File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: The Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors

TitleThe Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors
Authors
KeywordsCOVID-19
SARS-CoV-2
thyroid function tests
autoimmunity
interferon beta-1b
Issue Date2021
PublisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/endocrinology/
Citation
Frontiers in Endocrinology, 2021, v. 12, p. article no. 746602 How to Cite?
AbstractBackground: Some studies have indicated that interferon (IFN) may be valuable in COVID-19. We aimed to evaluate the impact of short-term IFN on incident thyroid dysfunction and autoimmunity among COVID-19 survivors. Methods: We included consecutive adults without known thyroid disorder admitted to Queen Mary Hospital for COVID-19 from July 2020 to January 2021 who had thyroid function tests (TFTs) and anti-thyroid antibodies measured both on admission and at three months. Results: 226 patients were included (median age 55.0 years; 49.6% men): 135 were IFN-treated. There tended to be more abnormal TFTs upon reassessment in IFN-treated patients (8.1% vs 2.2%, p=0.080). 179 patients (65.4% IFN-treated) had a complete reassessment of anti-thyroid antibodies. There were significant increases in titres of both anti-thyroid peroxidase antibodies (anti-TPO: baseline 29.21 units [IQR: 14.97 – 67.14] vs reassessment 34.30 units [IQR: 18.82 – 94.65], p<0.001) and anti-thyroglobulin antibodies (anti-Tg: baseline 8.23 units [IQR: 5.40 – 18.44] vs reassessment 9.14 units [IQR: 6.83 – 17.17], p=0.001) in the IFN-treated group but not IFN-naïve group. IFN treatment (standardised beta 0.245, p=0.001) was independently associated with changes in anti-TPO titre. Of the 143 patients negative for anti-TPO at baseline, 8 became anti-TPO positive upon reassessment (seven IFN-treated; one IFN-naïve). Incident anti-TPO positivity was more likely to be associated with abnormal TFTs upon reassessment (phi 0.188, p=0.025). Conclusion: IFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes.
Persistent Identifierhttp://hdl.handle.net/10722/305399
ISSN
2023 Impact Factor: 3.9
2023 SCImago Journal Rankings: 1.240
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorLui, DTW-
dc.contributor.authorHung, IFN-
dc.contributor.authorLee, CH-
dc.contributor.authorLee, ACH-
dc.contributor.authorTam, AR-
dc.contributor.authorPang, P-
dc.contributor.authorHo, TY-
dc.contributor.authorCheung, CYY-
dc.contributor.authorFong, CHY-
dc.contributor.authorLaw, CY-
dc.contributor.authorTo, KKW-
dc.contributor.authorLam, CW-
dc.contributor.authorChow, WS-
dc.contributor.authorWoo, YC-
dc.contributor.authorLam, KSL-
dc.contributor.authorTan, KCB-
dc.date.accessioned2021-10-20T10:08:51Z-
dc.date.available2021-10-20T10:08:51Z-
dc.date.issued2021-
dc.identifier.citationFrontiers in Endocrinology, 2021, v. 12, p. article no. 746602-
dc.identifier.issn1664-2392-
dc.identifier.urihttp://hdl.handle.net/10722/305399-
dc.description.abstractBackground: Some studies have indicated that interferon (IFN) may be valuable in COVID-19. We aimed to evaluate the impact of short-term IFN on incident thyroid dysfunction and autoimmunity among COVID-19 survivors. Methods: We included consecutive adults without known thyroid disorder admitted to Queen Mary Hospital for COVID-19 from July 2020 to January 2021 who had thyroid function tests (TFTs) and anti-thyroid antibodies measured both on admission and at three months. Results: 226 patients were included (median age 55.0 years; 49.6% men): 135 were IFN-treated. There tended to be more abnormal TFTs upon reassessment in IFN-treated patients (8.1% vs 2.2%, p=0.080). 179 patients (65.4% IFN-treated) had a complete reassessment of anti-thyroid antibodies. There were significant increases in titres of both anti-thyroid peroxidase antibodies (anti-TPO: baseline 29.21 units [IQR: 14.97 – 67.14] vs reassessment 34.30 units [IQR: 18.82 – 94.65], p<0.001) and anti-thyroglobulin antibodies (anti-Tg: baseline 8.23 units [IQR: 5.40 – 18.44] vs reassessment 9.14 units [IQR: 6.83 – 17.17], p=0.001) in the IFN-treated group but not IFN-naïve group. IFN treatment (standardised beta 0.245, p=0.001) was independently associated with changes in anti-TPO titre. Of the 143 patients negative for anti-TPO at baseline, 8 became anti-TPO positive upon reassessment (seven IFN-treated; one IFN-naïve). Incident anti-TPO positivity was more likely to be associated with abnormal TFTs upon reassessment (phi 0.188, p=0.025). Conclusion: IFN for COVID-19 was associated with modest increases in anti-thyroid antibody titres, and a trend of more incident anti-TPO positivity and abnormal TFTs during convalescence. Our findings suggest that clinicians monitor the thyroid function and anti-thyroid antibodies among IFN-treated COVID-19 survivors, and call for further follow-up studies regarding the clinical significance of these changes.-
dc.languageeng-
dc.publisherFrontiers Research Foundation. The Journal's web site is located at http://www.frontiersin.org/endocrinology/-
dc.relation.ispartofFrontiers in Endocrinology-
dc.rightsThis Document is Protected by copyright and was first published by Frontiers. All rights reserved. It is reproduced with permission.-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectCOVID-19-
dc.subjectSARS-CoV-2-
dc.subjectthyroid function tests-
dc.subjectautoimmunity-
dc.subjectinterferon beta-1b-
dc.titleThe Impact of Interferon Beta-1b Therapy on Thyroid Function and Autoimmunity Among COVID-19 Survivors-
dc.typeArticle-
dc.identifier.emailLui, DTW: dtwlui@hku.hk-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailLee, CH: pchlee@hku.hk-
dc.identifier.emailPang, P: pollpang@hku.hk-
dc.identifier.emailHo, TY: tipyinho@hku.hk-
dc.identifier.emailCheung, CYY: cyy0219@hku.hk-
dc.identifier.emailFong, CHY: kalofong@hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hku.hk-
dc.identifier.emailLam, CW: ching-wanlam@pathology.hku.hk-
dc.identifier.emailChow, WS: chowws01@hkucc.hku.hk-
dc.identifier.emailWoo, YC: wooyucho@hku.hk-
dc.identifier.emailLam, KSL: ksllam@hku.hk-
dc.identifier.emailTan, KCB: kcbtan@hkucc.hku.hk-
dc.identifier.authorityLui, DTW=rp02803-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityLee, CH=rp02043-
dc.identifier.authorityCheung, CYY=rp02243-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityLam, CW=rp00260-
dc.identifier.authorityLam, KSL=rp00343-
dc.identifier.authorityTan, KCB=rp00402-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3389/fendo.2021.746602-
dc.identifier.pmid34659128-
dc.identifier.pmcidPMC8515032-
dc.identifier.scopuseid_2-s2.0-85117140142-
dc.identifier.hkuros328331-
dc.identifier.volume12-
dc.identifier.spagearticle no. 746602-
dc.identifier.epagearticle no. 746602-
dc.identifier.isiWOS:000708377700001-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats